Share Price and Basic Stock Data
Last Updated: November 10, 2025, 11:13 pm
| PEG Ratio | -0.95 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Asarfi Hospital Ltd operates in the Hospitals & Medical Services industry, currently priced at ₹164 with a market capitalization of ₹322 Cr. The company reported a steady increase in sales, rising from ₹69 Cr in March 2023 to ₹116 Cr in March 2025, representing a compound annual growth rate (CAGR) of approximately 32.7%. Quarterly sales also reflected this upward trend, with reported figures of ₹20.05 Cr in December 2023 and climbing to ₹35.66 Cr by June 2025. This growth trajectory is indicative of Asarfi’s expanding operational capacity and market demand for healthcare services. The company’s operating profit margin (OPM) consistently stood around 20%, highlighting its efficiency in converting revenue into profit. The financial performance is bolstered by a robust increase in revenue from operations per share, which grew from ₹42.89 in March 2024 to ₹61.27 in March 2025. Overall, the revenue trends indicate a positive outlook for the company in a growing healthcare market.
Profitability and Efficiency Metrics
Asarfi Hospital Ltd’s profitability metrics reveal significant fluctuations and an overall positive trend. The net profit surged to ₹11 Cr in March 2025, a notable recovery from ₹4 Cr in March 2024, illustrating the company’s capacity to rebound effectively from previous challenges. The earnings per share (EPS) also improved considerably, from ₹2.14 in March 2024 to ₹5.58 in March 2025. However, the operating profit recorded mixed results, with figures dipping to ₹3.99 Cr in March 2024 before rebounding to ₹24 Cr in March 2025. Efficiency ratios, such as the cash conversion cycle (CCC), stood at -16 days in March 2025, indicating improved operational efficiency compared to previous periods. The interest coverage ratio (ICR) was reported at 7.61x, suggesting that the company comfortably meets its interest obligations. These profitability and efficiency metrics position Asarfi Hospital as a competitive player in the healthcare sector, although attention to operational consistency remains crucial.
Balance Sheet Strength and Financial Ratios
The balance sheet of Asarfi Hospital Ltd demonstrates a solid financial foundation, with total assets reported at ₹164 Cr as of March 2025, up from ₹93 Cr in March 2023. The company’s reserves increased significantly from ₹51 Cr in March 2024 to ₹62 Cr in March 2025, underlining its capacity for reinvestment and financial stability. Borrowings rose to ₹49 Cr, reflecting a strategic approach to leverage financing for growth. The company’s total debt-to-equity ratio stood at 0.59x, indicating a prudent level of debt relative to equity. Key financial ratios show a price-to-book value (P/BV) of 2.01x, suggesting a reasonable valuation given its growth prospects. Asarfi’s return on equity (ROE) was reported at 14.1%, while return on capital employed (ROCE) stood at 15.8%, both metrics indicating effective utilization of capital. Overall, the financial health of Asarfi Hospital is robust, though the increasing borrowings require close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Asarfi Hospital Ltd reflects a stable ownership structure that can influence investor confidence. Promoters hold a significant 61.17% stake, ensuring strong control over company decisions. The presence of foreign institutional investors (FIIs) remains minimal at 0.10%, while domestic institutional investors (DIIs) hold 3.19%. Public ownership stands at 35.55%, indicating a diversified investor base. The number of shareholders rose to 1,176 by June 2025, reflecting growing interest in the company’s performance. However, the fluctuation in DII holdings—from 2.33% in March 2024 to 3.19% in June 2025—suggests varying confidence levels among institutional investors. This stable yet conservative shareholding pattern may impact the stock’s liquidity and could deter aggressive market movements. Overall, the investor landscape is cautiously optimistic, but the low FII participation raises potential concerns regarding international investor sentiment.
Outlook, Risks, and Final Insight
Asarfi Hospital Ltd’s outlook appears promising, supported by strong revenue growth and improving profitability metrics. However, several risks could impact future performance. The company’s increasing reliance on borrowings may lead to higher financial costs if interest rates rise, potentially squeezing profit margins. Additionally, the fluctuating operational efficiency, as evidenced by variations in cash conversion cycle and operating profit, could pose challenges in maintaining consistent performance. On the positive side, the growing demand for healthcare services in India, coupled with Asarfi’s strategic expansion initiatives, presents significant opportunities for further growth. The company must focus on operational stability and effective debt management to capitalize on these opportunities. Asarfi Hospital is well-positioned to benefit from the expanding healthcare market, but maintaining operational efficiency will be critical to sustaining its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Asarfi Hospital Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 8.77 Cr. | 20.2 | 28.7/9.80 | 29.2 | 23.0 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 285 Cr. | 145 | 168/72.9 | 26.7 | 43.0 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 37,034 Cr. | 1,812 | 2,372/1,238 | 46.8 | 177 | 0.25 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 245 Cr. | 117 | 141/55.0 | 377 | 28.8 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 12,521.33 Cr | 523.55 | 119.93 | 67.95 | 0.06% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Dec 2023 | Mar 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Sales | 20.05 | 24.04 | 32.89 | 33.89 | 35.66 |
| Expenses | 16.04 | 20.05 | 25.90 | 28.64 | 28.63 |
| Operating Profit | 4.01 | 3.99 | 6.99 | 5.25 | 7.03 |
| OPM % | 20.00% | 16.60% | 21.25% | 15.49% | 19.71% |
| Other Income | 1.20 | -0.41 | 0.89 | 4.87 | 1.42 |
| Interest | 0.60 | 0.76 | 1.18 | 1.35 | 1.22 |
| Depreciation | 3.25 | 3.49 | 3.04 | 3.23 | 2.96 |
| Profit before tax | 1.36 | -0.67 | 3.66 | 5.54 | 4.27 |
| Tax % | 102.94% | -76.12% | 25.41% | 30.87% | 25.29% |
| Net Profit | -0.05 | -0.16 | 2.72 | 3.83 | 3.20 |
| EPS in Rs | -0.03 | -0.08 | 1.38 | 1.95 | 1.63 |
Last Updated: August 19, 2025, 11:20 pm
Below is a detailed analysis of the quarterly data for Asarfi Hospital Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 35.66 Cr.. The value appears strong and on an upward trend. It has increased from 33.89 Cr. (Mar 2025) to 35.66 Cr., marking an increase of 1.77 Cr..
- For Expenses, as of Jun 2025, the value is 28.63 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 28.64 Cr. (Mar 2025) to 28.63 Cr., marking a decrease of 0.01 Cr..
- For Operating Profit, as of Jun 2025, the value is 7.03 Cr.. The value appears strong and on an upward trend. It has increased from 5.25 Cr. (Mar 2025) to 7.03 Cr., marking an increase of 1.78 Cr..
- For OPM %, as of Jun 2025, the value is 19.71%. The value appears strong and on an upward trend. It has increased from 15.49% (Mar 2025) to 19.71%, marking an increase of 4.22%.
- For Other Income, as of Jun 2025, the value is 1.42 Cr.. The value appears to be declining and may need further review. It has decreased from 4.87 Cr. (Mar 2025) to 1.42 Cr., marking a decrease of 3.45 Cr..
- For Interest, as of Jun 2025, the value is 1.22 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.35 Cr. (Mar 2025) to 1.22 Cr., marking a decrease of 0.13 Cr..
- For Depreciation, as of Jun 2025, the value is 2.96 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3.23 Cr. (Mar 2025) to 2.96 Cr., marking a decrease of 0.27 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.27 Cr.. The value appears to be declining and may need further review. It has decreased from 5.54 Cr. (Mar 2025) to 4.27 Cr., marking a decrease of 1.27 Cr..
- For Tax %, as of Jun 2025, the value is 25.29%. The value appears to be improving (decreasing) as expected. It has decreased from 30.87% (Mar 2025) to 25.29%, marking a decrease of 5.58%.
- For Net Profit, as of Jun 2025, the value is 3.20 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Mar 2025) to 3.20 Cr., marking a decrease of 0.63 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.63. The value appears to be declining and may need further review. It has decreased from 1.95 (Mar 2025) to 1.63, marking a decrease of 0.32.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:54 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 43 | 54 | 65 | 69 | 81 | 116 |
| Expenses | 37 | 46 | 54 | 55 | 65 | 93 |
| Operating Profit | 6 | 8 | 11 | 14 | 16 | 24 |
| OPM % | 15% | 15% | 17% | 20% | 20% | 20% |
| Other Income | 0 | 0 | 1 | 2 | 2 | 8 |
| Interest | 1 | 1 | 1 | 1 | 3 | 4 |
| Depreciation | 2 | 3 | 3 | 4 | 9 | 13 |
| Profit before tax | 4 | 5 | 8 | 11 | 6 | 15 |
| Tax % | 27% | 26% | 26% | 26% | 33% | 25% |
| Net Profit | 3 | 4 | 6 | 8 | 4 | 11 |
| EPS in Rs | 21.48 | 28.83 | 46.79 | 5.53 | 2.14 | 5.58 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.33% | 50.00% | 33.33% | -50.00% | 175.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.67% | -16.67% | -83.33% | 225.00% |
Asarfi Hospital Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
Last Updated: September 5, 2025, 2:26 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 20 | 14 | 30 | 90 | 109 | 125 |
| Inventory Days | 23 | 13 | 16 | 26 | 32 | 30 |
| Days Payable | 156 | 23 | 34 | 91 | 445 | 171 |
| Cash Conversion Cycle | -113 | 5 | 11 | 25 | -304 | -16 |
| Working Capital Days | -10 | -38 | -36 | 18 | 3 | 50 |
| ROCE % | 25% | 29% | 26% | 11% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.37 | 2.31 |
| Diluted EPS (Rs.) | 5.37 | 2.31 |
| Cash EPS (Rs.) | 11.82 | 6.58 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 41.16 | 35.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 41.16 | 35.78 |
| Revenue From Operations / Share (Rs.) | 61.27 | 42.89 |
| PBDIT / Share (Rs.) | 15.79 | 9.01 |
| PBIT / Share (Rs.) | 9.35 | 4.54 |
| PBT / Share (Rs.) | 7.27 | 3.17 |
| Net Profit / Share (Rs.) | 5.37 | 2.11 |
| NP After MI And SOA / Share (Rs.) | 5.37 | 2.11 |
| PBDIT Margin (%) | 25.76 | 20.99 |
| PBIT Margin (%) | 15.25 | 10.58 |
| PBT Margin (%) | 11.86 | 7.39 |
| Net Profit Margin (%) | 8.77 | 4.93 |
| NP After MI And SOA Margin (%) | 8.77 | 4.93 |
| Return on Networth / Equity (%) | 13.05 | 5.91 |
| Return on Capital Employeed (%) | 14.97 | 7.93 |
| Return On Assets (%) | 6.45 | 2.70 |
| Long Term Debt / Equity (X) | 0.41 | 0.28 |
| Total Debt / Equity (X) | 0.59 | 0.45 |
| Asset Turnover Ratio (%) | 0.75 | 0.00 |
| Current Ratio (X) | 1.43 | 1.13 |
| Quick Ratio (X) | 1.37 | 1.08 |
| Inventory Turnover Ratio (X) | 59.15 | 0.00 |
| Interest Coverage Ratio (X) | 7.61 | 6.58 |
| Interest Coverage Ratio (Post Tax) (X) | 3.59 | 2.55 |
| Enterprise Value (Cr.) | 210.28 | 142.87 |
| EV / Net Operating Revenue (X) | 1.74 | 1.69 |
| EV / EBITDA (X) | 6.77 | 8.06 |
| MarketCap / Net Operating Revenue (X) | 1.35 | 1.52 |
| Price / BV (X) | 2.01 | 1.83 |
| Price / Net Operating Revenue (X) | 1.35 | 1.52 |
| EarningsYield | 0.06 | 0.03 |
After reviewing the key financial ratios for Asarfi Hospital Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 5.37, marking an increase of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.31 (Mar 24) to 5.37, marking an increase of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.82. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 11.82, marking an increase of 5.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 41.16. It has increased from 35.78 (Mar 24) to 41.16, marking an increase of 5.38.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 41.16. It has increased from 35.78 (Mar 24) to 41.16, marking an increase of 5.38.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.27. It has increased from 42.89 (Mar 24) to 61.27, marking an increase of 18.38.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 15.79. This value is within the healthy range. It has increased from 9.01 (Mar 24) to 15.79, marking an increase of 6.78.
- For PBIT / Share (Rs.), as of Mar 25, the value is 9.35. This value is within the healthy range. It has increased from 4.54 (Mar 24) to 9.35, marking an increase of 4.81.
- For PBT / Share (Rs.), as of Mar 25, the value is 7.27. This value is within the healthy range. It has increased from 3.17 (Mar 24) to 7.27, marking an increase of 4.10.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.11 (Mar 24) to 5.37, marking an increase of 3.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 5.37. This value is within the healthy range. It has increased from 2.11 (Mar 24) to 5.37, marking an increase of 3.26.
- For PBDIT Margin (%), as of Mar 25, the value is 25.76. This value is within the healthy range. It has increased from 20.99 (Mar 24) to 25.76, marking an increase of 4.77.
- For PBIT Margin (%), as of Mar 25, the value is 15.25. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 15.25, marking an increase of 4.67.
- For PBT Margin (%), as of Mar 25, the value is 11.86. This value is within the healthy range. It has increased from 7.39 (Mar 24) to 11.86, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 8.77, marking an increase of 3.84.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.77. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 8.77, marking an increase of 3.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.05. This value is below the healthy minimum of 15. It has increased from 5.91 (Mar 24) to 13.05, marking an increase of 7.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.97. This value is within the healthy range. It has increased from 7.93 (Mar 24) to 14.97, marking an increase of 7.04.
- For Return On Assets (%), as of Mar 25, the value is 6.45. This value is within the healthy range. It has increased from 2.70 (Mar 24) to 6.45, marking an increase of 3.75.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.41. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.41, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.59. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 0.59, marking an increase of 0.14.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.75. It has increased from 0.00 (Mar 24) to 0.75, marking an increase of 0.75.
- For Current Ratio (X), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 1.5. It has increased from 1.13 (Mar 24) to 1.43, marking an increase of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 1.08 (Mar 24) to 1.37, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 59.15. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 59.15, marking an increase of 59.15.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.61. This value is within the healthy range. It has increased from 6.58 (Mar 24) to 7.61, marking an increase of 1.03.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.59. This value is within the healthy range. It has increased from 2.55 (Mar 24) to 3.59, marking an increase of 1.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 210.28. It has increased from 142.87 (Mar 24) to 210.28, marking an increase of 67.41.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.74. This value is within the healthy range. It has increased from 1.69 (Mar 24) to 1.74, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 6.77. This value is within the healthy range. It has decreased from 8.06 (Mar 24) to 6.77, marking a decrease of 1.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.52 (Mar 24) to 1.35, marking a decrease of 0.17.
- For Price / BV (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from 1.83 (Mar 24) to 2.01, marking an increase of 0.18.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.35. This value is within the healthy range. It has decreased from 1.52 (Mar 24) to 1.35, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.06, marking an increase of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Asarfi Hospital Ltd:
- Net Profit Margin: 8.77%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.97% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.05% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.59
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.7 (Industry average Stock P/E: 119.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.59
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.77%